Pancreatic Cancer Research

ResearcherLMU KlinikumActive in the last 2 years

Waldemar H. Uhl

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7719-3192; OpenAlex author ID A5019361836, A5049744327, A5081229300, A5111564729. Sources: OpenAlex.

Their work

Papers
42 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
177
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 6 papers · 2020: 2 papers · 2021: 5 papers · 2022: 3 papers · 2023: 5 papers · 2024: 7 papers · 2025: 3 papers · 2026: 1 paper

Papers 42

  1. Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomi… Co-author DOI 10.1200/jco-25-03004↗
  2. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
  3. Perioperative outcomes in an age-adapted analysis of the German StuDoQ|Pancreas registry for PDAC. Co-author DOI 10.1186/s12893-024-02647-1↗
  4. Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO… Co-author DOI 10.1200/jco-24-01502↗
  5. A retrospective, multicentric, nationwide analysis of the impact of splenectomy on survival of pancreatic cancer patients. Co-author DOI 10.1007/s00423-024-03570-y↗
  6. Prognostic value of the CRM-status in pancreatic ductal adenocarcinoma - data from a regional cancer registry. Co-author DOI 10.1186/s12885-024-12995-z↗
  7. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… Co-author DOI 10.1245/s10434-024-15932-3↗
  8. ASO Author Reflections: Distal Pancreatectomy With and Without Portomesenteric Venous Resection for Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Pa… Co-author DOI 10.1245/s10434-024-16021-1↗
  9. Impact of preoperative chemotherapy on surgical results in 139 patients with locally advanced pancreatic cancer. Co-author DOI 10.21037/hbsn-23-426↗
  10. Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine. Co-author DOI 10.3390/cancers16142612↗
  11. Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as Potential New Biomarkers in Patients wi… Co-author DOI 10.3390/cancers16152726↗
  12. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… First author DOI 10.1016/j.annonc.2022.09.161↗
  13. GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells. Co-author DOI 10.1111/jcmm.17825↗
  14. Exploring Pain, Quality of Life, and Emotional Well-Being in Patients with Advanced Pancreatic Cancer Practicing Spiritual Meditation: A Pilot Study. Co-author DOI 10.1159/000529865↗
  15. Unusual paraneoplastic syndromes in pancreatic cancer: a case report of Lambert-Eaton myasthenic syndrome (LEMS) associated with intraductal papillary mucinous… Co-author DOI 10.21037/acr-22-108↗
  16. 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial. Co-author DOI 10.2967/jnumed.122.264827↗
  17. [Surgical treatment of pancreatic cancer-What is new?] Co-author DOI 10.1007/s00104-022-01618-7↗
  18. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancr… Co-author DOI 10.1053/j.gastro.2022.07.047↗
  19. Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40170-022-00298-5↗
  20. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-… Co-author DOI 10.1007/s00066-020-01680-2↗
  21. Functional metabolic phenotyping of human pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2021.07.23.452145↗
  22. Recurrence of Pancreatic Ductal Adenocarcinoma after Complete Histopathological Remission Caused by FOLFIRINOX. Co-author DOI 10.1159/000509231↗
  23. Late recurrences of pancreatic cancer in patients with long-term survival after pancreaticoduodenectomy. Co-author DOI 10.21037/jgo-20-433↗
  24. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells10071821↗
  25. [Indications for Surgery in Pancreatic Ductal Adenocarcinoma - Consensus Recommendations by the German Society for General and Visceral Surgery]. Last author DOI 10.1055/a-1161-9501↗
  26. Prognostic value and impact of cerebral metastases in pancreatic cancer. Co-author DOI 10.1080/00015458.2018.1549379↗
  27. Surprising Twist in the Plot - Sister Mary Joseph's Nodule of Pancreatic Cancer Mimicking Wound Infection after Umbilical Hernia Repair. Co-author DOI 10.1007/s12029-017-9975-0↗
  28. Evaluation of the MDACC clinical classification system for pancreatic cancer patients in an European multicenter cohort. Co-author DOI 10.1016/j.ejso.2018.12.012↗
  29. The impact of preoperative biliary stenting in pancreatic cancer: A case-matched study from the German nationwide pancreatic surgery registry (DGAV StuDoQ|Panc… Co-author DOI 10.1016/j.pan.2019.09.007↗
  30. Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer. Co-author DOI 10.1159/000497827↗
  31. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial. Co-author DOI 10.1186/s12885-019-6148-5↗
  32. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Co-author DOI 10.7150/thno.29247↗
  33. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, r… Co-author DOI 10.1186/s12885-018-5183-y↗
  34. FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer. Co-author DOI 10.21037/jgo.2018.01.07↗
  35. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicent… Co-author DOI 10.1016/j.surg.2016.02.019↗
  36. Ductal pancreatic adenocarcinoma. Last author DOI 10.3238/arztebl.2014.0396↗
  37. [S3-guideline exocrine pancreatic cancer]. Co-author DOI 10.1055/s-0033-1356220↗
  38. 'One also needs a bit of trust in the doctor ... ': a qualitative interview study with pancreatic cancer patients about their perceptions and views on informat… Co-author DOI 10.1093/annonc/mdt193↗
  39. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.26466↗
  40. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Co-author DOI 10.1093/annonc/mdr351↗
  41. Rare solid tumors of the pancreas as differential diagnosis of pancreatic adenocarcinoma. Co-author DOI 10.6092/1590-8577/791↗
  42. [R classification and pancreatic ductal adenocarcinoma--R 0 is R 0]. First author DOI 10.1055/s-0031-1281750↗

Closest collaborators

The 25 strongest of 177 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael B. Ghadimi · 11 shared papers, 2019–2026 · strength 1.51
  2. Andrea Tannapfel · 13 shared papers, 2011–2026 · strength 1.46
  3. Anke Reinacher‐Schick · 11 shared papers, 2018–2026 · strength 1.42
  4. Philipp Höhn · 9 shared papers, 2018–2024 · strength 1.38
  5. Chris Braumann · 9 shared papers, 2018–2024 · strength 1.29
  6. Robert Grützmann · 7 shared papers, 2019–2026 · strength 0.89
  7. Orlin Belyaev · 6 shared papers, 2019–2024 · strength 0.88
  8. Tobias Keck · 6 shared papers, 2019–2025 · strength 0.85
  9. Uwe A. Wittel · 6 shared papers, 2018–2026 · strength 0.76
  10. Andreas Minh Luu · 6 shared papers, 2018–2021 · strength 0.74
  11. Stefan Hubert Boeck · 4 shared papers, 2021–2026 · strength 0.72
  12. Johanna B. Munding · 8 shared papers, 2011–2021 · strength 0.70
  13. Jens Werner · 5 shared papers, 2019–2025 · strength 0.69
  14. Stephan A. Hahn · 5 shared papers, 2012–2024 · strength 0.60
  15. Dorota Łubgan · 4 shared papers, 2019–2026 · strength 0.58
  16. Henriette Golcher · 4 shared papers, 2019–2026 · strength 0.58
  17. Helmut Oettle · 4 shared papers, 2019–2026 · strength 0.58
  18. Marie Buchholz · 3 shared papers, 2023–2024 · strength 0.55
  19. Britta Majchrzak‐Stiller · 3 shared papers, 2023–2024 · strength 0.55
  20. Thomas Theodor Werner Seufferlein · 5 shared papers, 2014–2024 · strength 0.51
  21. Sabine Semrau · 3 shared papers, 2021–2026 · strength 0.50
  22. Rainer Fietkau · 3 shared papers, 2021–2026 · strength 0.50
  23. Ulrich Friedrich Wellner · 4 shared papers, 2019–2024 · strength 0.49
  24. Christiane J. Bruns · 3 shared papers, 2022–2024 · strength 0.48
  25. Markus Hecht · 2 shared papers, 2025–2026 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.